0001193125-13-474415.txt : 20131216 0001193125-13-474415.hdr.sgml : 20131216 20131216140432 ACCESSION NUMBER: 0001193125-13-474415 CONFORMED SUBMISSION TYPE: SC 13G PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20131216 DATE AS OF CHANGE: 20131216 SUBJECT COMPANY: COMPANY DATA: COMPANY CONFORMED NAME: OncoMed Pharmaceuticals Inc CENTRAL INDEX KEY: 0001302573 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 383572512 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G SEC ACT: 1934 Act SEC FILE NUMBER: 005-87757 FILM NUMBER: 131278582 BUSINESS ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 BUSINESS PHONE: 650-995-8200 MAIL ADDRESS: STREET 1: 800 CHESAPEAKE DRIVE CITY: REDWOOD CITY STATE: CA ZIP: 94063 FILED BY: COMPANY DATA: COMPANY CONFORMED NAME: CELGENE CORP /DE/ CENTRAL INDEX KEY: 0000816284 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 222711928 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: SC 13G BUSINESS ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 BUSINESS PHONE: (908)673-9000 MAIL ADDRESS: STREET 1: 86 MORRIS AVENUE CITY: SUMMIT STATE: NJ ZIP: 07901 SC 13G 1 d643223dsc13g.htm SCHEDULE 13G Schedule 13G

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

SCHEDULE 13G

Under the Securities Exchange Act of 1934

 

 

OncoMed Pharmaceuticals, Inc.

(Name of Issuer)

Common Stock, $0.001 par value per share

(Title of Class of Securities)

68234X102

(CUSIP Number)

December 4, 2013

(Date of Event Which Requires Filing of this Statement)

 

 

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

¨ Rule 13d-1(b)

x Rule 13d-1(c)

¨ Rule 13d-1(d)

 

 

 

13G

 

CUSIP No. 68234X102   Page 2 of 5 Pages

 

  1.   

Names of reporting persons

 

Celgene Corporation

  2.  

Check the appropriate box if a member of a group

(a)  ¨        (b)  ¨

 

  3.  

SEC use only

 

  4.  

Citizenship or place of organization

 

    Delaware

Number of

shares

beneficially

owned by

each

reporting

person

with:

    5.    

Sole voting power

 

    1,470,588 shares of Common Stock of the Issuer

   6.   

Shared voting power

 

    0

   7.   

Sole dispositive power

 

    1,470,588 shares of Common Stock of the Issuer

   8.   

Shared dispositive power

 

    0

  9.  

Aggregate amount beneficially owned by each reporting person

 

    1,470,588 shares of Common Stock of the Issuer

10.  

Check box if the aggregate amount in Row (9) excludes certain shares    ¨

 

11.  

Percent of class represented by amount in Row (9)

 

    5.0%

12.  

Type of reporting person

 

    CO

 

13G

 

CUSIP No. 68234X102    Page 3 of 5 Pages

 

SCHEDULE 13G

 

Item 1(a). Name of Issuer:

Oncomed Pharmaceuticals, Inc.

 

Item 1(b). Address of Issuer’s Principal Executive Offices:

800 Chesapeake Drive

Redwood City, California 94063

 

Item 2(a). Name of Person Filing:

Celgene Corporation

 

Item 2(b). Address of Principal Business Office:

86 Morris Avenue

Summit, New Jersey 07901

 

Item 2(c). Citizenship:

Delaware, U.S.A.

 

Item 2(d). Title of Class of Securities:

Common Stock, par value $0.001

 

Item 2(e) CUSIP Number:

68234X102

 

Item 3. If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

Not Applicable.

 

Item 4. Ownership.

Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.

 

  (a) Amount beneficially owned: 1,470,588 shares of Common Stock of the Issuer

 

  (b) Percent of class: 5.0%. Such percentage is based upon 29,384,647 outstanding shares of Common Stock of the Issuer as of December 2, 2013.

 

  (c) Number of shares as to which such person has:

 

  (i) Sole power to vote or to direct the vote: 1,470,588

 

  (ii) Shared power to vote or to direct the vote: 0

 

  (iii) Sole power to dispose or to direct the disposition of: 1,470,588

 

  (iv) Shared power to dispose or to direct the disposition of: 0

13G

 

CUSIP No. 68234X102    Page 4 of 5 Pages

 

Item 5. Ownership of Five Percent or Less of a Class.

If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following    ¨.

 

Item 6. Ownership of More than Five Percent on Behalf of Another Person.

Not Applicable.

 

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable.

 

Item 8. Identification and Classification of Members of the Group.

Not Applicable.

 

Item 9. Notice of Dissolution of Group.

Not Applicable.

 

Item 10. Certifications.

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Date: December 13, 2013

 

CELGENE CORPORATION
By:  

/s/ Thomas M. Perone

  Name:   Thomas M. Perone
  Title:   Assistant Secretary